NASDAQ:SNSS Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free SNSS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.38▼$5.3252-Week Range N/AVolume1.20 million shsAverage Volume4.33 million shsMarket Capitalization$96.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sunesis Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.Read More Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event SNSS Stock News HeadlinesDecember 20, 2023 | seekingalpha.comAQSZF Aequus Pharmaceuticals Inc.August 6, 2022 | thestreet.com4 Breakout Stocks to Watch Going Into Labor DayMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…January 14, 2022 | thestreet.com4 Stocks Under $10 to Trade NowSee More Headlines Receive SNSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2020Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SNSS CUSIP86732860 CIK1061027 Webwww.sunesis.com Phone650-266-3500FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-179.05% Return on Assets-72.27% Debt Debt-to-Equity RatioN/A Current Ratio7.74 Quick Ratio7.74 Sales & Book Value Annual Sales$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / BookN/AMiscellaneous Outstanding Shares18,093,000Free FloatN/AMarket Cap$96.26 million OptionableOptionable Beta2.27 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Judith A. Fox (Age 64)Chief Scientific Officer and Exec. VP of R&D Comp: $562.19kMr. Parvinder S. Hyare (Age 50)Interim CEO & Principal Exec. Officer Ms. Tina Gullotta (Age 46)Principal Financial Officer, VP of Fin. & Principal Accounting Officer Dr. Deborah A. ThomasSr. VP, Regulatory Affairs, Quality Assurance & PharmacovigilanceMr. Daniel N. Swisher Jr. (Age 58)Strategic Advisor Key CompetitorsEmergent BioSolutionsNYSE:EBSBolt BiotherapeuticsNASDAQ:BOLTHepion PharmaceuticalsNASDAQ:HEPAMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDAView All Competitors SNSS Stock Analysis - Frequently Asked Questions How were Sunesis Pharmaceuticals' earnings last quarter? Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.01. When did Sunesis Pharmaceuticals' stock split? Sunesis Pharmaceuticals shares reverse split on the morning of Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Dan Swisher Jr.'s approval rating as Sunesis Pharmaceuticals' CEO? 4 employees have rated Sunesis Pharmaceuticals Chief Executive Officer Dan Swisher Jr. on Glassdoor.com. Dan Swisher Jr. has an approval rating of 82% among the company's employees. What other stocks do shareholders of Sunesis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include Amarin (AMRN), QUALCOMM (QCOM), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Exelixis (EXEL) and Novavax (NVAX). This page (NASDAQ:SNSS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunesis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.